Amylyx Pharmaceuticals Inc

Stock Chart, Company Information, and Scan Results

$14.02(as of Oct 30, 11:27 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Amylyx Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$14.02
Ticker SymbolAMLX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees123
CountyUSA
Market Cap$1,527.5M
EBIDTA-196.3M
10-Day Moving Average14.65
P/E Ratio-6.60
20-Day Moving Average14.29
Forward P/E Ratio2.77
50-Day Moving Average12.57
Earnings per Share-2.49
200-Day Moving Average6.95
Profit Margin-Infinity%
RSI50.21
Shares Outstanding106.7M
ATR0.89
52-Week High16.96
Volume1,308,024
52-Week Low2.60
Most Recent Support Level13.88
Book Value167.9M
Most Recent Resistance Level14.63
P/B Ratio7.38
Upper Keltner16.29
P/S Ratio-4,972.43
Lower Keltner12.29
Debt-to-Equity Ratio16.29
Next Earnings Date11/06/2025
Cash Surplus36.7M
Next Ex-Dividend DateUnknown

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals Inc In Our Stock Scanner

As of Oct 30, 2025
example chart graphic
Scan Name: Bull FlagScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low PS RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.